MADRIGAL PHARMACEUTICALS, INC. ($MDGL)
Filing Information
| Accession Number | 0001628280-26-015775 |
|---|---|
| Form Type | 4 |
| Filing Date | Mar 7, 2026 |
| Document | View SEC Filing |
Transactions
14
Total Shares
13,716
Total Value
$853,992.52
P&L
+inf% (+$5,176,571.44)
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EVP and CFO | Common Stock | โ | Mar 4, 2026 | Grant/Award | 5,215 | $0.00 | $0.00 | 14,472 | Direct | โ | View Details | |
EVP and CFO | Common Stock | โ | Mar 6, 2026 | Sale | 646 | $431.94 | $279,033.24 | 13,826 | Direct | โ | View Details | |
EVP and CFO | Common Stock | โ | Mar 6, 2026 | Sale | 40 | $425.08 | $17,003.20 | 13,786 | Direct | โ | View Details | |
EVP and CFO | Common Stock | โ | Mar 6, 2026 | Sale | 420 | $426.86 | $179,282.80 | 13,366 | Direct | โ | View Details | |
EVP and CFO | Common Stock | โ | Mar 6, 2026 | Sale | 80 | $427.85 | $34,227.60 | 13,286 | Direct | โ | View Details | |
EVP and CFO | Common Stock | โ | Mar 6, 2026 | Sale | 160 | $429.00 | $68,639.20 | 13,126 | Direct | โ | View Details | |
EVP and CFO | Common Stock | โ | Mar 6, 2026 | Sale | 40 | $429.58 | $17,183.20 | 13,086 | Direct | โ | View Details | |
EVP and CFO | Common Stock | โ | Mar 6, 2026 | Sale | 120 | $430.90 | $51,708.40 | 12,966 | Direct | โ | View Details | |
EVP and CFO | Common Stock | โ | Mar 6, 2026 | Sale | 116 | $432.56 | $50,176.48 | 12,850 | Direct | โ | View Details | |
EVP and CFO | Common Stock | โ | Mar 6, 2026 | Sale | 160 | $434.20 | $69,472.00 | 12,690 | Direct | โ | View Details | |
EVP and CFO | Common Stock | โ | Mar 6, 2026 | Sale | 80 | $435.31 | $34,825.20 | 12,610 | Direct | โ | View Details | |
EVP and CFO | Common Stock | โ | Mar 6, 2026 | Sale | 80 | $436.69 | $34,935.20 | 12,530 | Direct | โ | View Details | |
EVP and CFO | Common Stock | โ | Mar 6, 2026 | Sale | 40 | $437.65 | $17,506.00 | 12,490 | Direct | โ | View Details | |
EVP and CFO | Stock Option (Right to Buy) | Derivative | Mar 4, 2026 | Grant/Award | 6,519 | $0.00 | $0.00 | 6,519 | Direct | โ | View Details |